Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313351426> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4313351426 endingPage "132.44" @default.
- W4313351426 startingPage "132.44" @default.
- W4313351426 abstract "Abstract GBM is the most common primary malignant brain tumor, carrying an ominous prognosis (< 2 years survival).Vγ9+ γδ (Vγ9+) T cells mediate major histocompatibility non restricted killing of tumor cells, suggesting Vγ9+ T cell- mediated adoptive immunotherapy may be of benefit in this disease. We established a protocol for ex-vivo expansion of Vγ9+ T cells from the peripheral blood (PB) of GBM patients, in whom Vγ9+ T cells consisted 0.55±0.58%(n=16) of the PB mononuclear cells (MC) just prior to surgical resection of the tumor (vs 0.91±0.42% in 9 healthy donors (HD), p<0.08). We found no correlation between % Vγ9+ T cells in patient PBMC and survival following surgical removal of the tumor. Nevertheless, short term culture of PBMC in the presence of a bisphosphonate, zoledronate (2μM) and 100 IU IL-2, expanded Vγ9+ T cells of all patients 522±466 fold, to consist 54±21% of the cultured MC (not significantly different from HD). The cultured cells were cytotoxic and expressed cytokines in response to GBM cell lines and autologous tumor derived cells. Furthermore, pre-treatment of the tumor with zoledronate, as well as with the clinical anti-GBM reagent temozolomide (TMZ), enhanced Vγ9+ T cell tumor recognition. These data suggest that adoptive immunotherapy employing autologously derived ex vivo activated and expanded Vγ9+T cells, in combination with zoledronate andTMZ, may lead to enhanced therapeutic responses in GBM patients." @default.
- W4313351426 created "2023-01-06" @default.
- W4313351426 creator A5011777787 @default.
- W4313351426 creator A5018857844 @default.
- W4313351426 creator A5036600686 @default.
- W4313351426 creator A5046709612 @default.
- W4313351426 creator A5059698412 @default.
- W4313351426 date "2013-05-01" @default.
- W4313351426 modified "2023-09-27" @default.
- W4313351426 title "Vγ9+ γδ T cells of glioblastoma multiforme (GBM) patients expanded ex vivo kill GBM cell lines and secrete IFNγ in vitro, suggesting their therapeutic potential. (P2108)" @default.
- W4313351426 doi "https://doi.org/10.4049/jimmunol.190.supp.132.44" @default.
- W4313351426 hasPublicationYear "2013" @default.
- W4313351426 type Work @default.
- W4313351426 citedByCount "0" @default.
- W4313351426 crossrefType "journal-article" @default.
- W4313351426 hasAuthorship W4313351426A5011777787 @default.
- W4313351426 hasAuthorship W4313351426A5018857844 @default.
- W4313351426 hasAuthorship W4313351426A5036600686 @default.
- W4313351426 hasAuthorship W4313351426A5046709612 @default.
- W4313351426 hasAuthorship W4313351426A5059698412 @default.
- W4313351426 hasConcept C137061746 @default.
- W4313351426 hasConcept C147483822 @default.
- W4313351426 hasConcept C150903083 @default.
- W4313351426 hasConcept C154317977 @default.
- W4313351426 hasConcept C167672396 @default.
- W4313351426 hasConcept C202751555 @default.
- W4313351426 hasConcept C203014093 @default.
- W4313351426 hasConcept C207001950 @default.
- W4313351426 hasConcept C26291073 @default.
- W4313351426 hasConcept C2776090121 @default.
- W4313351426 hasConcept C2777389519 @default.
- W4313351426 hasConcept C2777701055 @default.
- W4313351426 hasConcept C2778227246 @default.
- W4313351426 hasConcept C502942594 @default.
- W4313351426 hasConcept C55493867 @default.
- W4313351426 hasConcept C71924100 @default.
- W4313351426 hasConcept C86803240 @default.
- W4313351426 hasConcept C8891405 @default.
- W4313351426 hasConcept C90375314 @default.
- W4313351426 hasConceptScore W4313351426C137061746 @default.
- W4313351426 hasConceptScore W4313351426C147483822 @default.
- W4313351426 hasConceptScore W4313351426C150903083 @default.
- W4313351426 hasConceptScore W4313351426C154317977 @default.
- W4313351426 hasConceptScore W4313351426C167672396 @default.
- W4313351426 hasConceptScore W4313351426C202751555 @default.
- W4313351426 hasConceptScore W4313351426C203014093 @default.
- W4313351426 hasConceptScore W4313351426C207001950 @default.
- W4313351426 hasConceptScore W4313351426C26291073 @default.
- W4313351426 hasConceptScore W4313351426C2776090121 @default.
- W4313351426 hasConceptScore W4313351426C2777389519 @default.
- W4313351426 hasConceptScore W4313351426C2777701055 @default.
- W4313351426 hasConceptScore W4313351426C2778227246 @default.
- W4313351426 hasConceptScore W4313351426C502942594 @default.
- W4313351426 hasConceptScore W4313351426C55493867 @default.
- W4313351426 hasConceptScore W4313351426C71924100 @default.
- W4313351426 hasConceptScore W4313351426C86803240 @default.
- W4313351426 hasConceptScore W4313351426C8891405 @default.
- W4313351426 hasConceptScore W4313351426C90375314 @default.
- W4313351426 hasIssue "1_Supplement" @default.
- W4313351426 hasLocation W43133514261 @default.
- W4313351426 hasOpenAccess W4313351426 @default.
- W4313351426 hasPrimaryLocation W43133514261 @default.
- W4313351426 hasRelatedWork W1621856421 @default.
- W4313351426 hasRelatedWork W1983363132 @default.
- W4313351426 hasRelatedWork W2032597637 @default.
- W4313351426 hasRelatedWork W2055715607 @default.
- W4313351426 hasRelatedWork W2072008518 @default.
- W4313351426 hasRelatedWork W2159389701 @default.
- W4313351426 hasRelatedWork W2174267452 @default.
- W4313351426 hasRelatedWork W2953447703 @default.
- W4313351426 hasRelatedWork W2969859807 @default.
- W4313351426 hasRelatedWork W3174314443 @default.
- W4313351426 hasVolume "190" @default.
- W4313351426 isParatext "false" @default.
- W4313351426 isRetracted "false" @default.
- W4313351426 workType "article" @default.